Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-AnalysisShixue Chen, Yi Hu, Jinliang Wang et al.|Frontiers in Oncology|2021Cited by 125
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsZhaozhen Wu, Yi Hu, Pengfei Cui et al.|Clinical Medicine Insights Oncology|2021Cited by 64
Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint InhibitorsZhibo Zhang, Jinliang Wang|Frontiers in Immunology|2020Cited by 54
Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancerDanyang Sun, Junxun Ma, Jinliang Wang et al.|Cancer Immunology Immunotherapy|2019Cited by 45